Blog
RSS FeedPosted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after ...
Posted by Michael Wonder on 15 Feb 2019
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
15 February 2019 - NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in ...
Posted by Michael Wonder on 10 Feb 2019
Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology
7 February 2019 - Patient involvement in drug evaluation decision making is increasing. ...
Posted by Michael Wonder on 08 Feb 2019
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...
Posted by Michael Wonder on 04 Feb 2019
Mother of four is denied cancer drug that could save her life
2 February 2019 - A British nurse with four children is being denied potentially life-saving cancer treatment that was approved ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 18 Jan 2019
NICE OK for Bravtovi skin cancer drug
18 January 2019 - NICE has recommended Pierre Fabre’s Bravtovi (encorafenib) and Mektovi (binimetinib) combination as an option for some ...
Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...
Posted by Michael Wonder on 09 Jan 2019
Stivarga final NICE recommendation for hepatocellular carcinoma
9 January 2019 - Bayer’s Stivarga has received a final green light from NICE for use by the NHS to ...
Posted by Michael Wonder on 21 Dec 2018
NICE recommends Lenvima for advanced liver cancer
21 December 2018 - NICE has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma ...
Posted by Michael Wonder on 19 Dec 2018
NICE authorises MSD's Keytruda for stage III melanoma
19 December 2018 - MSD’s Keytruda has been given a green light for use within the EU as an adjuvant ...
Posted by Michael Wonder on 10 Dec 2018
NICE turns down Opdivo/Yervoy combo for kidney cancer
10 December 2018 - NICE has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma. ...
Posted by Michael Wonder on 07 Dec 2018
NICE OKs NHS funding for Gilead’s CAR T-cell therapy
7 December 2018 - Gilead’s CAR T-cell therapy Yescarta will be available on the NHS to some adults with lymphoma. ...